Skip to main content
Back
KKPCF logo

Kaken Pharmaceutical Co., Ltd.

Data quality: 100%
Overbought
KKPCF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$26.00
$0.00 (0.00%)
Mkt Cap: 984.58M
Day Range
$22.30 $26.00
52-Week Range
$22.30 $28.12
Volume
2
50D / 200D Avg
$26.04 / $26.36
Prev Close
$26.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 9.4 3.7
Net Margin % 14.8 3.8
Rev Growth 5Y % 5.8 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 5.82% annually over 5 years — modest growth
Earnings grew 73.77% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 25.39B in free cash flow
P/E of 0.07 — trading at a low valuation
PEG of 0.15 suggests growth is underpriced

Growth

Revenue Growth (5Y)
5.82%
Revenue (1Y)30.52%
Earnings (1Y)73.77%
FCF Growth (3Y)89.81%

Quality

Return on Equity
9.41%
ROIC10.08%
Net Margin14.83%
Op. Margin22.37%

Safety

Debt / Equity
0.03
Current Ratio3.67
Interest Coverage751.21

Valuation

P/E Ratio
0.07
P/B Ratio0.01
EV/EBITDA-2.34
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 30.52% Revenue Growth (3Y) 13.51%
Earnings Growth (1Y) 73.77% Earnings Growth (3Y) 60.11%
Revenue Growth (5Y) 5.82% Earnings Growth (5Y) 0.99%
Profitability
Revenue (TTM) 94.04B Net Income (TTM) 13.95B
ROE 9.41% ROA 7.32%
Gross Margin 62.24% Operating Margin 22.37%
Net Margin 14.83% Free Cash Flow (TTM) 25.39B
ROIC 10.08% FCF Growth (3Y) 89.81%
Safety
Debt / Equity 0.03 Current Ratio 3.67
Interest Coverage 751.21 Dividend Yield 0.05%
Valuation
P/E Ratio 0.07 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 0.15
EV/EBITDA -2.34 Dividend Yield 0.05%
Market Cap 984.58M Enterprise Value -49.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 94.04B 72.04B 72.98B 76.03B 74.98B
Net Income 13.95B 8.03B 5.44B 9.55B 13.41B
EPS (Diluted) 365.42 212.66 144.79 251.44 347.37
Gross Profit 58.53B 38.54B 39.56B 41.58B 40.91B
Operating Income 21.03B 9.51B 8.00B 17.06B 17.79B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 190.42B 171.62B 166.33B 165.18B 163.33B
Total Liabilities 37.79B 27.87B 29.49B 26.86B 27.08B
Shareholders' Equity 152.63B 143.76B 136.26B 137.75B 136.26B
Total Debt 3.85B 3.85B 3.85B 3.85B 3.85B
Cash & Equivalents 54.09B 50.63B 59.56B 61.03B 63.71B
Current Assets 111.38B 106.97B 109.90B 110.61B 113.66B
Current Liabilities 30.35B 19.02B 20.84B 19.05B 21.28B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#93 of 1024
71
Custom Deep Value Investing (Seth Klarman)
#467 of 820
38
Growth Price/Sales Ratio Focus (Ken Fisher)
#388 of 616
27
Value Defensive Investing (Benjamin Graham)
#620 of 708
5

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026